Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX) is a healthcare company (biotechnology) based in the United States. The share price is $14.29, down 2.99% on the day, which values the company at $1.56B. Price as of 17 Nov 2026, 17:41 UTC, from Yahoo Finance.
Key facts
- Share price
- $14.29−2.99% today
- Market value
- $1.56B
- P/E ratio
- 5.9×last 12 months
- Funk Score
- 55/100
- Against its own history
- Below its usual priceusual price $17.59
- 200-week average
- $14.944% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Nurix Therapeutics, Inc. in more detail
NRIX trades at 5.9× its last twelve months' earnings, -11.2× next year's expected earnings, 2.2× sales. Measured against its own history, the price is 19% below what its usual multiples would imply ($17.59) — below its usual price. It sits 4% below its 200-week average of $14.94.
Over the last five fiscal years Nurix Therapeutics, Inc. has compounded revenue 36.3% a year. Its Funk Score is 55 out of 100 (financial strength 6.9, profitability 2.0, growth 9.3, value 3.8, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
2 of the superinvestors tracked here hold NRIX, including Julian and Felix Baker (0.6% of the portfolio), Cathie Wood (0.3% of the portfolio).
Superinvestors holding NRIX
2 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors0.57% of portfolio · $113M · Q2 2026
- Cathie Wood ARK Invest0.25% of portfolio · $43.9M · added · Q3 2026
Nurix Therapeutics, Inc. (NRIX): questions and answers
What is NRIX's P/E ratio?
Nurix Therapeutics, Inc. trades at 5.9× its last twelve months' earnings and -11.2× next year's expected earnings.
What is Nurix Therapeutics, Inc.'s market cap?
Nurix Therapeutics, Inc. is valued at $1.56B at a share price of $14.29.
Is NRIX overvalued or undervalued?
Against its own history, NRIX is below its usual price: the price is 19% below the $17.59 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is NRIX above its 200-week moving average?
No. NRIX is 4.3% below its 200-week average of $14.94. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Nurix Therapeutics, Inc. growing?
Over the last five fiscal years Nurix Therapeutics, Inc.'s revenue grew 36.3% a year.
Does NRIX pay a dividend?
Nurix Therapeutics, Inc. does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Nurix Therapeutics, Inc. (NRIX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NRIX
Underlying data: Yahoo Finance; company filings with the SEC.